CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced upcoming oral presentations highlighting its transcription factor and protein degradation capabilities at the 18th Annual Drug Discovery Chemistry Meeting. The hybrid meeting will be held April 10–13, 2023, at the Hilton Bayfront in San Diego, CA, and virtually.
View original post here:
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
Recommendation and review posted by Fredricko
